Intermediate hepatocellular carcinoma: the role of transarterial therapy.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2015-11-06 DOI:10.2217/HEP.15.32

F. Chegai, A. Orlacchio, S. Merolla, S. Monti, L. Mannelli

引用次数: 12

Abstract

According to Barcelona Clinic Liver Cancer, the recommended first-line treatment for patients with intermediate stage of hepatocellular carcinoma (HCC) is transarterial chemoembolization. Patients with intermediate stage of HCC represent 20% with a 2-year survival of approximately 50%. Nowadays, transarterial therapies have proved precious in the treatment of hepatic malignancies. During the last years, there were important developments in practiced transarterial therapies and their efficacy is still controversial. The purpose of this review is to discuss in further details these transarterial therapies that have been used to treat cases of HCC.

查看原文本刊更多论文

中间肝癌:经动脉治疗的作用。

根据巴塞罗那临床肝癌，中期肝细胞癌(HCC)患者推荐的一线治疗是经动脉化疗栓塞。HCC中期患者占20%，2年生存率约为50%。目前，经动脉治疗在肝脏恶性肿瘤的治疗中已被证明是宝贵的。在过去的几年里，经动脉治疗的实践有了重要的发展，但其疗效仍然存在争议。本综述的目的是进一步详细讨论这些经动脉治疗HCC的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.